GB Sciences Inc (GBLX)

[Nighthawk_1]

I extinguished ALL shares I ever had in ALL marijuana producing companies. Soon to go the way of the DODO bird...LOL Also, if people really did not know, but marijuana plants are bad for the environment. Sucks up so much water that with all the growers, they are taking away everyone's water supply.

[Nighthawk_1]

Soon, quite soon, marijuana will be a thing of the past. Just my opinion. People will begin to realize that they are wasting their money on this that does nothing to help them sustain themselves in life. Even if marijuana becomes fully legalized, people will eventually get away from it. In the 1960's, it was a fad, then it went away. We are in this scenario again. Younger kids are beginning to realize this and will change everything.

[loanshark007]

John POS still around?

[Silver plated]

Where are you getting this information if they are not releasing updates?

[SmallCapStockAlert]

GBLX has been making progress very fast. I expect price-moving news soon. Time to load up.

[SmallCapStockAlert]

Been quiet for far too long. Company is working on many different medical diseases. Expect news soon that could send shares much higher!

[loanshark007]

I wonder how far out they are from producing revenue.

[loanshark007]

No, I believe he is with INQD now.

[SmallCapStockAlert]

GBLX has not been discovered yet. GBLX PhAROS AI Drug Discovery Engine and their promising pipeline for Parkinson's
Disease, Advanced Heart Problems, Pain and Inflammation, are about to enter into human trials for Parkinson's with LabCorp as their CRO could be a very big success story. If successful, this could be an incredibly high-priced stock.

Both our President, Andrea Small-Howard, PhD, MBA, and our Chairman, John Poss, have issued Gb Sciences' Shareholder Letter summarizing key developments from 2022 and providing the company's strategic plans for 2023. Read the full update: https://t.co/YC7YZkTjo5

— GB Sciences, Inc. (@gbsciencesinc) March 8, 2023

[Think1st]

Is leslie bockor is on the board of directors??

[SmallCapStockAlert]

$GBLX #AI is a biotech gamechanger and GBLX shares are only 2 cents. https://richardacavalli.wixsite.com/greenplanetmicrocaps/gb-sciences-is-combining-ai-biotech

[SmallCapStockAlert]

GBLX has the most advanced AI drug development technology called PhAROS and has already generated very promising data for Parkinson's, heart disease, pain and anxiety and more and is starting human trials on Parkinson's the year. I think shares are highly undervalued now and ould easily see multiples higher in coming weeks and months. Very strong management and technology.

[FairviewInvestor]

holding long and strong. This dog will have its day within next 18 months. 5x-10x very possible.

Might get an R/S first. that's a risk.

time will tell, don't gamble with what you aren't prepared to lose

[hardfive10]

Time for this one to move back up. Talk is cheap, actually getting the patent is gold. https://www.google.com/url?sa=t&source=web&rct=j&url=https://finance.yahoo.com/amphtml/news/gb-sciences-granted-u-patent-120000472.html&ved=2ahUKEwjBvIGb6af2AhXqlmoFHQnADuEQyM8BKAB6BAgREAI&usg=AOvVaw33fiTpMs53lOCOM_v17-F-

[FairviewInvestor]

GBLX sells Las Vegas Cannabis operation for $8M. pivot business away from marijuana

https://www.globenewswire.com/news-release/2022/01/11/2364758/0/en/Gb-Sciences-Completes-8-Million-Sale-of-Las-Vegas-Cannabis-Facility.html

[FairviewInvestor]

$6M market capitalization. 317.43M shares outstanding.

[hardfive10]

https://gbsciences.newswire.com/news/gb-sciences-presenting-covid-related-cytokine-release-syndrome-results-21493280

[fishbrains]

[loanshark007]

John POSs still running the show here?

[FairviewInvestor]

Market Cap is basically in BK land considering IP... just needs one big player to have a need for their pharma approach and this is a 4 bagger instantly

[FairviewInvestor]

Been tracking long time. haven't seen a dilution in many, many months.

[FairviewInvestor]

Is this ever going to go?

[hardfive10]

http://www.itnewsonline.com/news/GB-Sciences-Featured--Speaking-at-the-SACHS-Associates-4th-Annual-Neuroscience-Innovation-Forum/4427

[FairviewInvestor]

Why the slow sell-off on Friday? It's not dilution that I can see

[fishbrains]

GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief
https://finance.yahoo.com/news/gb-sciences-publishes-study-creation-110000469.html

Cool stuff!

[XeoX_X]

Need new management here.

$GBLX

[Bossman1981]

Yes Sir! We both agreed!

[st007]

That's how she moved on her way over $1 last time. I'd rather have a slow and steady climber than a quick P&D. $GBLX

[Bossman1981]

Slow moving

[wasdeafonce]

Is this dog dead?

[DropLine]

GW deal will fire up 420 bios... this is one.

$GBLX

[chattsy11]

Lots of patent activity!!!

[FairviewInvestor]

Added many times over past few months under .055..

I do think that the company has good potential with all the MJ that is in the future.

good luck to longs

Let's go

[FairviewInvestor]

Still Holding Full. So much potential in 2021.

MJ space is on uptick.

Patents, IP will only gain in value as larger Co's seek competitive advantage

[DropLine]

Here shaarky, shaarky... "play it as you see it"... lmao!

$GBLX

[JEB11584]

Please correct me if I am wrong, but I thought the original sale of the stake in the Louisiana operation was 8 million. Am I thinking of something else or did they renegotiate?

[DropLine]

LAS VEGAS, NV / ACCESSWIRE / January 12, 2021 / GB Sciences, Inc. (OTCQB:GBLX) completed the sale of its remaining interest in GB Sciences Louisiana LLC ("GBSLA") on December 16, 2020 .

In November 2019 , the Company entered into a Membership Interest Purchase Agreement (the "Agreement") with Wellcana Plus, LLC ("Wellcana"), whereby Wellcana would acquire the Company's 50% membership interest in GBSLA. Since then, certain modifications of the Agreement had taken place so GB Sciences would be paid a total of $4,900 ,000: $4,150,000 in one lump sum at closing, in addition to the $750,000 already received, rather than over time to complete the sale to Wellcana. A portion of the proceeds from this sale were used to completely satisfy the Company's obligations to Iliad Reseach and Trading, LP .
John Poss , CEO and Chairman of GB Sciences , stated, "We have the highest respect for Wellcana and wish them continued success in bringing relief to patients in Louisiana . That said, completing this sale is a nice way to close out a tough year."
Andrea Small-Howard , Chief Science Officer and Director of both GB Sciences and GBS Global Biopharma, Inc. , remarked, "This brings us a big step forward in turning our attention from the past towards the future, where we can focus 100% of our attention and capital on developing our existing cannabis-based combination therapies and on new research to enrich our already promising patent portfolio."

[st007]

I'm still here. I got out, but then jumped back in 03s. $GBLX

[st007]

Been holding steady in 04s. MACD turning up. $GBLX

[jjr04001]

I think heading lower first to .035ish

[DropLine]

Holding .04 over the past few weeks... looks like this is getting ready for the next leg up...

$GBLX

[jjr04001]

.0418 these prices are great. I may have to buy back in soon.

[jjr04001]

I'm out. Good luck to you!

[st007]

Yep! I was here when we were in dollar land. I just notified my investor buddies as well. This board has always been quiet.
GLTU!
$GBLX

[jjr04001]

Nice job! $GBLX

[st007]

GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations
10:05 AM ET 12/8/20 | Dow Jones

LAS VEGAS, NV / ACCESSWIRE / December 8, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,857,107 entitled "Cannabinoid-Containing Complex Mixtures for the Treatment of Mast-Cell-Associated or Basophil-Mediated Inflammatory Disorders" today, Dec. 8, 2020. This U.S. patent is assigned to GBS Global Biopharma (GBS), Inc., GB Sciences' Canadian entity. GBS's new U.S. patent protects methods of using GBS's proprietary cannabinoid-containing complex mixtures (CCCM(TM)) for treating Mast Cell Activation Syndrome (MCAS). MCAS is a severe immunological condition in which mast cells inappropriately and excessively release inflammatory mediators, resulting in a range of severe chronic hyperinflammatory symptoms and life-threatening anaphylaxis attacks.

"Receiving our patent for the treatment of MCAS using GBS's CCCM(TM) is an important milestone in the development of this urgently needed medicine. There is no single recommended treatment for MCAS patients. Instead, they attempt to manage MCAS symptoms primarily by avoiding 'triggers' and using rescue medicines for their severe hyperinflammatory attacks. Therefore, MCAS patients need new therapeutic options to control their mast cell related symptoms, and our CCCM(TM) were designed to simultaneously control multiple inflammatory pathways within mast cells as a comprehensive treatment option," explained Dr. Andrea Small-Howard, Chief Science Officer and Director of both GB Sciences, Inc. and GBS Global Biopharma, Inc. "Our company is strategically targeting MCAS for two additional reasons. By focusing on a rare disease with no known cure, our company can apply for the U.S. Food and Drug Administration's expedited approval process, which allows clinically successful treatments to get to market both quicker and more cost-effectively. Gaining approval from the U.S. FDA for the entire anti-inflammatory market would be extremely time-consuming and cost-prohibitive. Demonstrating that our CCCM(TM) are safe for the treatment of MCAS would favorably position our Company for clinical testing of these CCCM(TM) as potential treatments for other related inflammatory disorders, such as inflammatory bowel disease, thereby widening the target market and drastically shortening the development cycle and costs."

GBS's intellectual property portfolio contains multiple patent families covering different CCCM(TM) containing novel combinations of active pharmaceutical ingredients that are complex mixtures composed of natural or synthetic homologs of cannabis-derived ingredients. In addition to the U.S. patent issued for its MCAS CCCM(TM), GBS's intellectual property portfolio currently contains four patents that are issued in the U.S. with corresponding patents issued internationally. Seven nonprovisional patent applications and three provisional patent applications are pending in the U.S. and 29 patent applications have been filed internationally drawn to CCCM(TM) for the treatment of neuropathic pain, inflammatory disorders, cardiovascular disease, neurodegenerative conditions and a variety of other clinically unmet needs.

"Our focus on this rare disease offers strategic advantages in development and entry into the lucrative anti-inflammatory market," said John Poss, CEO and Chairman of GB Sciences, Inc. "This U.S. patent further validates our drug discovery platform and strengthens our intellectual property portfolio of unique CCCM(TM), each targeting one of up to 50 specific clinical applications."

About GB Sciences, Inc. and GBS Global Biopharma, Inc.

GB Sciences, Inc. (OTCQB:GBLX), through its Canadian entity GBS Global Biopharma, Inc., is a dedicated biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets.

[st007]

Looking good. Added more today.

[jjr04001]

Here we go!

[jjr04001]

People will start coming in $GBLX

[jjr04001]

Pop coming, check out that weekly chart $GBLX